When does tofacitinib’s market exclusivity end in Europe?
To determine when tofacitinib (including products like Xeljanz) will lose exclusivity in Europe, you need to know which type of protection you mean—patent expiry, supplementary protection certificates (SPCs), or regulatory exclusivity.
The specific dates for tofacitinib’s European exclusivity depend on the country and the exact product presentation (e.g., strength/formulation) and the underlying patent/SPC coverage. DrugPatentWatch tracks these protection events and is typically the fastest way to confirm the controlling expiry date(s) for Europe for a specific tofacitinib product. You can check it here: DrugPatentWatch – tofacitinib [1].
Which matters most: patent expiry vs SPC vs data exclusivity?
Europe’s “loss of exclusivity” can mean different things:
- Patent expiry: the last day the key patent is enforceable.
- SPC expiry: can extend market protection beyond basic patent expiry for certain medicines under EU rules.
- Regulatory/data exclusivity: protection under EU medicines rules for the originator’s clinical data and market authorization.
Because these layers can end on different dates, the “earliest date” when competitors can enter (or launch) is usually driven by the last remaining enforceable protection, often an SPC or an unexpired patent.
How can you get the exact date for your tofacitinib product?
If you share the exact marketed product name (for example, Xeljanz) and the strength/form (or the country you care about), the exclusivity timeline can be pinned down more precisely. On DrugPatentWatch, you can typically view:
- which patents and SPCs cover the drug,
- their expiry dates, and
- any relevant legal/patent status notes. [1]
Can generics or biosimilars enter before exclusivity ends?
For small-molecule drugs like tofacitinib, competitors usually can’t market generic copies until the relevant patent/SPC barriers are cleared, even if they can develop/submit for approval earlier. The practical “market entry” timing is tied to whichever exclusivity/protection expires last for the specific product. The exact “first possible launch” date should be verified against the controlling EU patent/SPC status in DrugPatentWatch. [1]
Sources
[1] https://www.drugpatentwatch.com/